The Impact on Anti-Mullerian Hormone (AMH), uterine fibroid size and uterine artery patency following Uterine Fibroid Embolization (UFE) with a resorbable embolic agent
| Autor: | Ganesh Vigneswaran, Sachin Modi, Ying Cheong, Drew Maclean, Timothy Bryant, Sameer Umranikar, Nigel Hacking |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Anti-Mullerian Hormone medicine.medical_specialty Uterine fibroids medicine.medical_treatment Urology Embolic Agent medicine.artery medicine Humans Embolization Prospective Studies Ovarian reserve Uterine artery biology Leiomyoma business.industry Obstetrics and Gynecology Anti-Müllerian hormone General Medicine Uterine Artery Embolization medicine.disease female genital diseases and pregnancy complications Uterine Artery Treatment Outcome Reproductive Medicine Uterine fibroid embolization Uterine Neoplasms biology.protein Quality of Life Female business |
| Popis: | The effect of Uterine Fibroid Embolization on fertility and ovarian reserve remains uncertain. We assessed the impact of a new resorbable, spherical particle (Gelbead) on concentration of Anti-Mullerian (AMH) hormone, fibroid volume and uterine artery patency. This prospective cohort study recruited consecutive patients from July 2017 to June 2018. Serum AMH, fibroid and uterine volume, UFS-QOL (uterine fibroid score-quality of life) scores were measured prior to and at 1 month and/or 3 months post embolization. Twenty-four participants were enrolled (median age 44 years, uterine volume 484 cm 3, initial dominant fibroid volume 167 cm 3). One patient was lost to follow-up. AMH (median ± SD) immediately prior to embolization was 3.2 ± 13.7 pmol/L. At 1-month postembolization, AMH was 4.1 ± 8.6 pmol/L and at 3 months 4.4 ± 8.6 pmol/L. We found no significant difference in AMH levels between baseline and at 1 month (p = 0.58) or baseline and 3 months (p = 0.17). The median dominant uterine fibroid volume decreased (167 to 64 cm 3, p < 0.001). At 3 months post-embolization, 17/23 patients had patent uterine arteries bilaterally (73.9%). UFE with Gel-bead did not significantly affect AMH at 3 months post embolization, whilst maintaining a high rate of uterine artery patency. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|